PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : I

Records returned : 85 (on 17 May 2024 at 10:33:27).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Ibandronic acid
No Information Returned
Ibrutinib
No Information Returned
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Preferred
07.01.01
10.01.01
10.03.02
Ibuprofen
Osteoarthritis
Green
Formulations :
  • Gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
5% gel. This is the least costly option for primary care.
07.01.01
10.01.01
10.03.02
Ibuprofen
Dysmenorrhoea
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Reserved for patients with swallowing difficulties
07.01.01
10.01.01
10.03.02
Ibuprofen
Ductus arteriosus closure
Red
Formulations :
  • Infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Paediatric consultants only
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Red
Formulations :
  • Infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Restricted for patients where an oral NSAID is not suitable
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain
Red
Formulations :
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Restricted for patients where an oral NSAID is not suitable.
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Capsules
  • Modified release capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Ibuprofen lysine
No Information Returned
Ibuprofen sodium dihydrate
No Information Returned
Ibuprofen/pseudoephedrine hydrochloride
No Information Returned
Icatibant acetate
No Information Returned
Ichthammol
No Information Returned
Icosapent
No Information Returned
Idarubicin hydrochloride
No Information Returned
Idarucizumab
No Information Returned
Idebenone
No Information Returned
Idoxuridine in dimethyl sulfoxide
No Information Returned
Ifosfamide
No Information Returned
Iloprost
No Information Returned
Imatinib mesilate
No Information Returned
Imidapril hydrochloride
No Information Returned
Imiglucerase
No Information Returned
Imipenem with cilastatin
No Information Returned
04.03.01
04.07.03
07.04.02
Imipramine hydrochloride
Pain (Neuropathic)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.03.01
04.07.03
07.04.02
Imipramine hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Imiquimod
No Information Returned
Inclisiran
No Information Returned
Indacaterol maleate
No Information Returned
Indacaterol/glycopyrronium
No Information Returned
Indacaterol/mometasone
No Information Returned
Indapamide
No Information Returned
Indinavir
No Information Returned
07.01.01
10.01.01
Indometacin
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Capsules
  • Capsules (slow release)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Only for use in gout. ASPH restricted to rheumatology only.
07.01.01
10.01.01
Indometacin
Ductus arteriosus closure
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
Important
Paediatric consultants only
07.04.01
Indoramin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Graft versus Host Disease (GVHD)
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Behcet's syndrome
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Highly specialist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Specilaist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Connective tissue disease
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
Influenza
No Information Returned
Influenza H1N1(Split viron, inactivated, adjuvanted)
No Information Returned
Influenza H1N1(Whole viron, vero, inactivated)
No Information Returned
Ingenol mebutate
No Information Returned
Inosine pranobex
No Information Returned
Inotuzumab
No Information Returned
INR blood testing reagents
No Information Returned
Ins degludec/liraglutide
No Information Returned
06.01.01
Insulin aspart
Diabetes Mellitus
Green
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Insulin degludec
No Information Returned
Insulin detemir
No Information Returned
06.01.01
Insulin glargine
Diabetes Mellitus
Green
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Insulin glargine/lixisenatide
No Information Returned
Insulin glulisine
No Information Returned
Insulin human
No Information Returned
Insulin human inhaled
No Information Returned
06.01.01
Insulin Lispro
Diabetes Mellitus
Green
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Insulin zinc suspension
No Information Returned
Insulin zinc suspension (Crystalline)
No Information Returned
Interferon alpha
No Information Returned
Interferon beta
No Information Returned
Interferon gamma
No Information Returned
Intravenous nutrition supplements
No Information Returned
Iodine
No Information Returned
Iodine compounds
No Information Returned
Iodoform
No Information Returned
Ipecacuanha
No Information Returned
Ipilimumab
No Information Returned
Ipratropium bromide
No Information Returned
Irbesartan
No Information Returned
Irbesartan with diuretic
No Information Returned
Irinotecan hydrochloride
No Information Returned
Iron and folic acid
No Information Returned
Iron carboxymaltose
No Information Returned
Iron dextran
No Information Returned
Iron sorbitol
No Information Returned
Iron sucrose
No Information Returned
Isavuconazole
No Information Returned
Isocarboxazid
No Information Returned
Isometheptene mucate
No Information Returned
Isoniazid
No Information Returned
Isophane insulin
No Information Returned
Isopropyl alcohol
No Information Returned
Isosorbide dinitrate
No Information Returned
Isosorbide mononitrate
No Information Returned
Isosorbide mononitrate with aspirin
No Information Returned
Isotretinoin
No Information Returned
01.06.01
Ispaghula husk
Constipation
Green
Formulations :
  • Sachets (granules)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Isradipine
No Information Returned
Itraconazole
No Information Returned
Ivabradine
No Information Returned
Ivacaftor
No Information Returned
Ivermectin
No Information Returned
Ixazomib
No Information Returned
10.01.03
13.05.02
13.05.03
Ixekizumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Ixekizumab
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Ixekizumab
Non-radiographic axial spondyloarthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Ixekizumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More